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Introduction
Micronutrient deficiencies are common among women in 
low-income and middle-income countries mainly due to 
inadequate dietary intake and limited diversity of fruits, 
vegetables, animal protein, and fortified foods.1 The 
burden and severity of micronutrient deficiencies are 
exacerbated during pregnancy because of increased 
demands of both the mother and the growing fetus.2 It is 
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Summary
Background Micronutrient deficiencies are common among women in low-income and middle-income countries. 
Data from randomised trials suggest that maternal multiple micronutrient supplementation decreases the risk of low 
birthweight and potentially improves other infant health outcomes. However, heterogeneity across studies suggests 
influence from effect modifiers. We aimed to identify individual-level modifiers of the effect of multiple micronutrient 
supplements on stillbirth, birth outcomes, and infant mortality in low-income and middle-income countries. 
Methods This two-stage meta-analysis of individual patient included data from 17 randomised controlled trials done 
in 14 low-income and middle-income countries, which compared multiple micronutrient supplements containing 
iron-folic acid versus iron-folic acid alone in 112 953 pregnant women. We generated study-specific estimates and 
pooled subgroup estimates using fixed-effects models and assessed heterogeneity between subgroups with the χ² test 
for heterogeneity. We did sensitivity analyses using random-effects models, stratifying by iron-folic acid dose, and 
exploring individual study effect.
Findings Multiple micronutrient supplements containing iron-folic acid provided significantly greater reductions in 
neonatal mortality for female neonates compared with male neonates than did iron-folic acid supplementation alone 
(RR 0·85, 95% CI 0·75–0·96 vs 1·06, 0·95–1·17; p value for interaction 0·007). Multiple micronutrient supplements 
resulted in greater reductions in low birthweight (RR 0·81, 95% CI 0·74–0·89; p value for interaction 0·049), small-
for-gestational-age births (0·92, 0·87–0·97; p=0·03), and 6-month mortality (0·71, 0·60–0·86; p=0·04) in anaemic 
pregnant women (haemoglobin <110g/L) as compared with non-anaemic pregnant women. Multiple micronutrient 
supplements also had a greater effect on preterm births among underweight pregnant women (BMI <18·5 kg/m²; 
RR 0·84, 95% CI 0·78–0·91; p=0·01). Initiation of multiple micronutrient supplements before 20 weeks gestation 
provided greater reductions in preterm birth (RR 0·89, 95% CI 0·85–0·93; p=0·03). Generally, the survival and birth 
outcome effects of multiple micronutrient supplementation were greater with high adherence (≥95%) to 
supplementation. Multiple micronutrient supplements did not significantly increase the risk of stillbirth or neonatal, 
6-month, or infant mortality, neither overall or in any of the 26 examined subgroups.
Interpretation Antenatal multiple micronutrient supplements improved survival for female neonates and provided 
greater birth-outcome benefits for infants born to undernourished and anaemic pregnant women. Early initiation in 
pregnancy and high adherence to multiple micronutrient supplements also provided greater overall benefits. Studies 
should now aim to elucidate the mechanisms accounting for differences in the effect of antenatal multiple 
micronutrient supplements on infant health by maternal nutrition status and sex.
Funding None.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
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well established that iron-deficiency anaemia in pregnancy 
can lead to decreased birthweight, and insufficient folate 
concentrations in the periconceptional period increases 
the risk of neural tube defects and other adverse 
outcomes.3–5 Deficiencies in other micronutrients 
including vitamins A, B-complex, D, E, zinc, calcium, 
copper, magnesium, selenium, and iodine are also 
prevalent in low-income and middle-income countries and 
can lead to poor pregnancy, fetal growth, and child health 
outcomes.3,6–8 As such, maternal multiple micronutrient 
supplementation including iron-folic acid is a potential 
intervention to improve maternal and child health as 
compared with iron-folic acid supplementation alone.
The 2017 Cochrane Systematic Review and meta-
analysis that assessed the effect of maternal multiple 
micronutrient supplements in pregnancy on infant 
mortality identified 19 randomised controlled trials and 
pooled data from 17 of these studies.6 Provision of 
multiple micronutrient supplements in combination 
with iron-folic acid during pregnancy reduced the risk of 
low birthweight (<2500 g; relative risk [RR] 0·88, 95% CI 
0·85–0·91) and small-for-gestational-age births (0·92, 
0·86–0·98), but had no significant effect on perinatal 
(1·01, 0·91–1·13) and neonatal mortality (1·06, 0·92–1·22) 
as compared with iron-folic acid supplementation alone.6 
There was moderate heterogeneity, as measured by I², of 
the effect of multiple micronutrient supplements on 
some birth outcomes across published trials but 
substantial heterogeneity for perinatal mortality. A 
previously published pooled analysis of 12 multiple 
micronutrient supplements trials also indicated the effect 
of multiple micronutrient supplements on birthweight 
may be greater in pregnant women with higher BMI.9
In 2016, WHO reviewed their antenatal care 
recommendations and acknowledged that policy makers 
in populations with a high prevalence of nutritional 
deficiencies might wish to provide multiple micronutrient 
supplements containing iron and folic acid. However, 
WHO did not universally recommend multiple 
micronutrient supplements, noting that there was 
evidence of benefit but also some evidence of harm.10 The 
existing data also precluded definitive conclusions if any 
subgroups experience greater benefits or harm due to 
multiple micronutrient supplements.
In this study we aimed to elucidate individual-level 
effect modifiers that might alter the impact of maternal 
multiple micronutrient supplements on stillbirth, birth 
outcomes, and infant mortality. We aimed to identify 
subgroups of pregnant women and infants who might 
experience greater benefit or harm from multiple 
micronutrient supplements and explore the sources of 
the heterogeneity across randomised trials.
Methods
In this two-stage meta-analysis of individual patient 
data, we identified potential studies for inclusion 
Research in context
Evidence before this study
Micronutrient deficiencies are common in pregnant women in 
low-income and middle-income countries. However, debate 
persists regarding the current WHO recommendation to 
provide pregnant women with iron-folic acid supplementation 
alone, rather than multiple micronutrient supplements 
containing other essential micronutrients in addition to 
iron-folic acid during routine antenatal care. In the past 
two decades, more than 20 randomised trials have examined 
the effect of multiple micronutrient supplements during 
pregnancy, compared with iron-folic acid alone, on maternal 
and child health outcomes. The 2017 Cochrane review and 
meta-analysis established that provision of daily oral multiple 
micronutrient supplements reduced the risk of low birthweight 
(<2500 g) and small-for-gestational-age births, but had no 
overall effect on perinatal and neonatal mortality as compared 
with iron-folic acid alone.
The recently updated 2016 WHO antenatal care 
recommendations acknowledged that policy makers in 
populations with a high prevalence of maternal nutritional 
deficiencies might wish to provide multiple micronutrient 
supplements. However, WHO does not universally recommend 
multiple micronutrient supplements, noting: “There is some 
evidence of additional benefit of multiple micronutrient 
supplements containing 13–15 different micronutrients 
(including iron and folic acid) over iron and folic acid 
supplements alone, but there is also some evidence of risk, 
and some important gaps in the evidence”.
Added value of this study
This study uses the most detailed approach to analysing existing 
trial data on multiple micronutrient supplements. Previous 
meta-analyses identified overall benefits of multiple 
micronutrient supplements in terms of birth size, but our 
findings show that specific subgroups experience mortality 
benefits, notably female neonates. Women with indicators of 
malnutrition during pregnancy who took multiple micronutrient 
supplements also had greater reductions in low birthweight, 
preterm, and small-for-gestational-age births. We found no 
evidence that multiple micronutrient supplements significantly 
increased the risk of stillbirth or neonatal, 6-month, or infant 
mortality, neither overall or in any of the 26 examined 
subgroups.
Implications of the available evidence
This novel analysis identified subgroups of mothers and infants 
that might benefit the most from multiple micronutrient 
supplements. This new evidence suggests that WHO might 
wish to re-evaluate the balance of benefits and harms of 
universal multiple micronutrient supplementation in their 
antenatal care recommendations. 
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through a review of recent meta-analyses.6,11,12 We then 
updated this list of potential studies using the search 
strategy employed by the 2015 Cochrane Review to 
identify randomised controlled trials published up to 
July 20, 2015.6 We also reviewed the references of 
included trials and systematic reviews; there were no 
language restrictions.
Eligible studies were randomised controlled trials of 
multiple micronutrient supplements for pregnant 
women, containing at least three micronutrients; were 
done in low-income and middle-income countries as 
defined by the World Bank; included a control group that 
had received iron and folic acid supplements as part of 
the trial or as standard of care; whose authors presented 
data on birth outcomes, stillbirth, or infant mortality; and 
whose authors agreed to participate in this new individual 
patient data study. We excluded trials or trial groups that 
used lipid-based micronutrient supplements and 
micronutrient-fortified powders as these provided 
additional calories and nutrients that might have 
independent effects on outcomes of interest.
All outcomes, subgroups, and statistical methods were 
defined a priori. Outcomes of interest included: stillbirth, 
early neonatal (≤7 days age), neonatal (≤28 days age), 
6-month (≤180 days age), and infant (≤365 days age) 
mortality. Birth outcomes included: birthweight, very low 
birthweight (<2000 g), low birthweight (<2500 g), early 
preterm (<34 weeks gestation), preterm (<37 weeks 
gestation), small-for-gestational-age (<10th percentile of 
weight-for-gestational-age and sex as defined by Oken13 
and Intergrowth14 standards), and large-for-gestational-
age (>90th percentile as defined by Oken13 and 
Intergrowth14 standards). Births that occurred before 
33 weeks or after week 43 were excluded from 
Intergrowth14 analyses because small-for-gestational-age 
and large-for-gestational-age cutoffs were not defined for 
these gestational ages at the time of analysis.
We assessed the effect of multiple micronutrient 
supplements on all outcomes within the following 
subgroups selected based on biological plausibility and 
inclusion in previous meta-analyses: gestational age at 
randomisation (trimesters and <20 weeks vs ≥20 weeks), 
parity (1 child vs ≥2 children), maternal age (<18 years vs 
≥18 years and <20 years vs ≥20 years), maternal 
underweight at randomisation (BMI <18·5 kg/m² vs 
≥18·5 kg/m²), maternal anaemia at randomisation 
(<110 g/L vs ≥110 g/L), maternal stature (<150 cm vs 
≥150 cm), maternal education (none vs ≥1 year), infant sex 
(male vs female), and adherence to trial regimen 
(≥95% vs <95%). We examined the effect of multiple 
micronutrient supplements on stillbirth and mortality 
outcomes by the presence of a skilled birth attendant at 
delivery (yes vs no).
We contacted principal investigators of each study and 
invited them to participate in this study. Eight trials 
provided individual-level data to the Harvard T.H. Chan 
investigators (ERS and CRS) and nine independently 
conducted the subgroup analyses in accordance with the 
study protocol and using the same statistical analysis 
code. We calculated non-parametric relative risk or mean 
difference estimates and corresponding 95% CIs for 
individually randomised trials. We calculated estimates 
and 95% CIs for cluster randomised trials using methods 
consistent with the primary published paper.
We pooled study-specific relative risk and mean 
difference estimates using fixed effects models using 
STATA version 14 METAN command. We excluded trials 
which did not contribute at least one subject to all strata 
within a subgroup analysis. Heterogeneity within strata 
was quantified using the I² test statistic and 
corresponding p value, while heterogeneity between 
subgroups was assessed with the χ² test for heterogeneity. 
We qualitatively assessed study quality using the Child 
Health Epidemiology Reference Group standards.15 As a 
sensitivity analysis for individual subgroup effects, we 
generated pooled subgroup estimates using random-
effects models; we also examined overall and subgroup 
effects separately for trials using the same dose of iron in 
the multiple micronutrient supplements and comparison 
group and again for the trials using a lower dose iron in 
the multiple micronutrient supplements group than the 
comparison group. In addition, we did an influence 
analysis for significant results whereby we presented 
pooled estimates omitting each study, one at a time 
(appendix pp 218–220).16 To assess publication bias and 
small study effects we visually inspected funnel-plots 
(appendix pp 221–224). All individual trials were 
approved by their respective ethics committees. The 
pooling study protocol was approved by the 
Harvard T. H. Chan School of Public Health IRB 
(15-2969).
Role of the funding source
There was no funding source for this study. The 
corresponding author had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
We identified 19 randomised controlled trials that met 
our inclusion criteria, 17 of which were included in this 
meta-analysis.17–33 Two were not included; one study 
declined to participate and one could not locate the 
primary data.34,35 Table 1 provides a summary of trials 
included in the meta-analysis. The trials included 
112 953 pregnant women and study-specific sample size 
ranged from 20022 to 44 567,31 with two studies 
contributing more than two-thirds of total participants.26,31 
Eight trials used the United Nations multiple 
micronutrient preparation (UNIMMAP; multiple 
micronutrient supplements formulations in appendix 
p 1).20,21,23,26–30 All trials used multiple micronutrient 
supplements preparations that included at least eight 
micronutrients in addition to iron-folic acid. The 
See Online for appendix
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prevalence of effect modifiers and cumulative incidence 
of study outcomes by trial are presented in the appendix 
(pp 3, 4). All trials were graded low or moderate risk of 
bias (appendix p 2). Funnel plots did not provide clear 
evidence of publication bias or small study effects 
(appendix pp 221–224).
Figure 1 presents subgroup-specific pooled effect sizes 
for the following outcomes: stillbirth, neonatal mortality, 
infant mortality, low birthweight, preterm, and small-for-
gestational-age births as per the Oken standard. Forest 
plots for all subgroup meta-analyses are presented in the 
appendix (pp 5–205). Table 2 presents the effect of 
maternal multiple micronutrient supplements on 
stillbirth, neonatal mortality, mortality to 6 months, and 
infant mortality stratified by potential effect modifiers. 
We did not identify any factors that significantly modified 
the effect of multiple micronutrient supplements on 
stillbirth. In meta-analyses including all livebirths, there 
was no overall effect of multiple micronutrient 
supplements on mortality at any timepoint; however, 
there were several subgroups for which multiple 
micronutrient supplements provided significant survival 
benefits. We found sex modified the effect of multiple 
micronutrient supplements on survival in the early 
neonatal, neonatal, and infant periods (p values for 
heterogeneity: 0·047, 0·007, 0·04; table 2; appendix p 23). 
Multiple micronutrient supplements significantly 
reduced the risk of neonatal mortality by 15% among 
females (95% CI 4–25) with a similar magnitude of 
reduction for early neonatal, 6 months, and infant 
mortality. Significant mortality benefits of multiple 
micronutrient supplements for females were also found 
at all timepoints in random effects sensitivity analyses 
(appendix p 206). Multiple micronutrient supplements 
provided significantly greater 6-month mortality 
reduction among anaemic pregnant women as compared 
with non-anaemic pregnant women (RR 0·71, 95% CI 
0·60–0·86 vs 0·93, 0·78–1·11; p value for heterogeneity 
0·04). Maternal adherence to the intervention also 
modified the effect of multiple micronutrient 
supplements on infant mortality, with survival benefits 
for infants born to women with higher than 95% 
adherence to the supplements (table 2). No subgroup had 
significantly increased risk of stillbirth or neonatal, 
6 month, or infant mortality in both fixed and random 
effects meta-analyses (table 2 and appendix p 206).
Among all livebirths, multiple micronutrient 
supplements significantly reduced the risk of very low 
Location Years of study Study 
design
Participants Study population
Fawzi,24 1998 Dar es Salaam, Tanzania 1995–1997 RCT 1075 HIV-infected pregnant women 12–27 weeks gestation
Christian,17 2003 Sarlahi, Nepal 1998–2001 cRCT 4926 Pregnant women
Ramakrishnan,18 
2003
Cuernavaca, Mexico 1997–2000 RCT 873 Pregnant women <13 weeks gestation
Friis,19 2004 Harare, Zimbabwe 1996–1997 RCT 1669 Pregnant women 22–36 weeks gestation including 
725 HIV-infected women
Kaestel,20 2005 Bissau, Guinea-Bissau 2001–02 RCT 2100 Pregnant women <37 weeks gestation
Osrin,21 2005 Dhanusha and Mahottari 
Districts, Nepal
2002–04 RCT 1200 Singleton pregnant women between 12–20 weeks 
gestation
Gupta,22 2007 East Delhi, India 2002–03 RCT 200 Pregnant women with BMI <18·5 kg/m², 24–32 weeks 
gestation
Zagre,23 2007 Maradi, Niger 2004–06 cRCT 2902 Pregnant women <28 weeks gestation
Fawzi,25 2007 Dar es Salaam, Tanzania 2001–04 RCT 8468 HIV-uninfected pregnant women of 12–27 weeks 
gestation
Shankar,26 2008 Lombok island, Indonesia 2001–04 cRCT 31 290 Pregnant women (34% first, 43% second, and 23% third 
trimester)
Zeng,27 2008 Shaanxi Province, China 2002–06 cRCT 3811 Pregnant women (folic acid-only group excluded)
Roberfroid,28 2008 Hounde health district, 
Burkina Faso
2004–06 RCT 1426 Pregnant women
Bhutta,29 2009 Bilal colony, Karachi, Kot Diji, 
Sindh, Pakistan
2002–04 cRCT 2378 Pregnant women <16 weeks gestation
Persson,30 2012 Matlab, Bangladesh 2001–03 RCT 4436 Pregnant women between 6–8 weeks gestation
West,31 2014 Gaibandha and Rangpur, 
Bangladesh
2007–12 cRCT 44 567 Pregnant women (79% <13 weeks gestation)
Ashorn,32 2015 Mangochi District, Malawi 2011–13 RCT 929 Pregnant women <20 weeks gestation (excluding 
lipid-based nutrient supplement group)
Adu-Afarwuah,34 
2015
Somanya-Kpong, Ghana 2009–11 RCT 703 Pregnant women <20 weeks gestation (excluding 
lipid-based nutrient supplement group)
RCT=randomised control trial. cRCT=cluster randomised control trial.
Table 1: Characteristics of trials included in the meta-analysis
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Figure: The effect of multiple 
micronutrient supplements 
containing iron-folic acid 
compared with iron-folic 
acid alone on (A) stillbirth, 
(B) neonatal mortality, 
(C) infant mortality, 
(D) low birthweight, 
(E) preterm birth, and 
(F) small-for-gestational-age
as defined by the Oken 
standard,13 stratified by 
modifiers of interest
A  Stillbirth B  Neonatal mortality C  Infant mortality
Infant sex
   Male
   Female
Gestational age at enrolment
   <20 weeks
   ≥20 weeks
Maternal adherence to regimen
   <95% adherence
   ≥95% adherence
Maternal age
   <20 years
   ≥20 years
Parity
   First birth
   Second+ birth
Maternal underweight at enrolment
   BMI <18·5 kg/m²
   BMI ≥18·5 kg/m²
Maternal stature
   Height <150 cm
   Height ≥150 cm
Maternal haemoglobin at enrolment
   Anaemic (haemoglobin >110 g/L)
   Non-anaemic (haemoglobin ≥110 g/L)
Maternal education
   None
   ≥1 year formal education
Skilled birth attendant
   Yes
   No
Overall
10·5 1·50·75 1·25 10·5 1·50·75 1·25 10·5 1·50·75 1·25
D  Low birthweight E  Preterm birth F  Small-for-gestational age
Infant sex
   Male
   Female
Gestational age at enrolment
   <20 weeks
   ≥20 weeks
Maternal adherence to regimen
   <95% adherence
   ≥95% adherence
Maternal age
   <20 years
   ≥20 years
Parity
   First birth
   Second+ birth
Maternal underweight at enrolment
   BMI <18·5 kg/m²
   BMI ≥18·5 kg/m²
Maternal stature
   Height <150 cm
   Height ≥150 cm
Maternal haemoglobin at enrolment
   Anaemic (haemoglobin >110 g/L)
   Non-anaemic (haemoglobin ≥110 g/L)
Maternal education
   None
   ≥1 year formal education
Overall
Pooled relative risk with 95% CI
10·6 1·20·7 0·8 0·9 1·1 0·90·6 1·20·7 0·8 1·11 10·6 1·20·7 0·8 0·9 1·1
Articles
e1095 www.thelancet.com/lancetgh   Vol 5   November 2017
Stillbirth Neonatal mortality (≤28 days) 6-month mortality (≤180 days) Infant mortality (≤365 days)
n Relative risk  
(95% CI)
p value 
heterogeneity
n Relative risk  
(95% CI)
p value 
heterogeneity
n Relative risk   
(95% CI)
p value 
heterogeneity
n Relative risk 
(95% CI)
p value 
heterogeneity
Overall, fixed 
effects
16 0·92 (0·86–0·99) ·· 12 0·98 (0·90–1·05) ·· 9 0·93 (0·85–1·00) ·· 8 0·97 (0·88–1·06) ··
Overall, random 
effects
16 0·97 (0·85–1·11) ·· 12 0·99 (0·89–1·09) ·· 9 0·93 (0·86–1·00) ·· 8 0·97 (0·88–1·06) ··
Infant sex 16 ·· 0·88 12 ·· 0·007 9 ·· 0·06 8 ·· 0·04
Male ·· 0·92 (0·82–1·03) ·· ·· 1·06 (0·95–1·17) ·· ·· 0·98 (0·89–1·09) ·· ·· 1·05 (0·93–1·18) ··
Female ·· 0·91 (0·80–1·03) ·· ·· 0·85 (0·75–0·96) ·· ·· 0·85 (0·75–0·95) ·· ·· 0·87 (0·77–0·99) ··
Gestational age 
at enrolment
10 0·05 10 0·60 7 0·10 7 0·57
<20 weeks .. 0·97 (0·89–1·06) .. .. 0·99 (0·90–1·09)   .. .. 0·96 (0·87–1·05)   .. ..  0·98 (0·89–1·07)   ..
≥20 weeks ·· 0·81 (0·70–0·95) ·· ·· 0·94 (0·81–1·10) ·· ·· 0·82 (0·69–0·96) ·· ·· 0·89 (0·64–1·23) ··
Maternal 
adherence to 
regimen
11 0·96 9 0·05 6 0·11 5 0·02
<95% 
Adherence
·· 0·92 (0·83–1·01) ·· ·· 1·05 (0·94–1·17) ·· ·· 0·98 (0·88–1·09) ·· ·· 1·06 (0·94–1·20) ··
≥95% 
Adherence
·· 0·92 (0·85–0·99) .. ·· 0·88 (0·77–1·01) .. ·· 0·85 (0·74–0·97) ·· ·· 0·85 (0·74–0·97) ..
Maternal age 16 0·26 9 0·51 8 0·68 8 0·87
< 20 years ·· 0·99 (0·85–1·16) ·· ·· 0·95 (0·83–1·10) ·· ·· 0·96 (0·84–1·09) ·· ·· 0·98 (0·86–1·13) ··
≥ 20 years ·· 0·90 (0·83–0·97) ·· ·· 1·01 (0·92–1·12) ·· ·· 0·92 (0·84–1·02) ·· ·· 0·97 (0·87–1·09) ··
Parity 15 0·06 12 0·26 9 0·76 8 0·87
First birth ·· 1·01 (0·90–1·14) ·· ·· 0·93 (0·83–1·04) ·· ·· 0·94 (0·84–1·04) ·· ·· 0·97 (0·85–1·10) ··
≥ Second 
birth
·· 0·88 (0·80–0·96) ·· ·· 1·02 (0·91–1·14) ·· ·· 0·92 (0·82–1·02) ·· ·· 0·96 (0·85–1·08) ··
Maternal BMI 
at enrolment
12 0·53 11 0·61 8 0·60 7 0·95
<18·5 kg/m² ·· 0·90 (0·78–1·04) ·· ·· 1·01 (0·86–1·20) ·· ·· 0·96 (0·83–1·12) ·· ·· 0·97 (0·84–1·13) ··
≥18·5 kg/m² ·· 0·95 (0·87–1·04) ·· ·· 0·96 (0·88–1·06) ·· ·· 0·92 (0·84–1·01) ·· ·· 0·98 (0·88–1·09) ··
Maternal height 14 0·38 10 0·98 7 0·84 6 0·58
<150 cm ·· 0·96 (0·86–1·08) ·· ·· 0·97 (0·86–1·08) ·· ·· 0·92 (0·83–1·02) ·· ·· 0·98 (0·87–1·11) ··
≥150 cm ·· 0·90 (0·81–1·00) ·· ·· 0·96 (0·86–1·08) ·· ·· 0·91 (0·81–1·02) ·· ·· 0·93 (0·81–1·06) ··
Maternal 
haemoglobin at 
enrolment
13 0·16 10 0·54 8 0·04 7 0·95
Anaemic 
(haemoglobin 
<110 g/L)
·· 0·79 (0·66–0·94) ·· ·· 0·87 (0·73–1·03) ·· ·· 0·71 (0·60–0·86) ·· ·· 1·00 (0·73–1·30) ··
Non-anaemic 
(haemoglobin 
≥110 g/L)
·· 0·94 (0·79–1·12) ·· ·· 0·94 (0·79–1·11) ·· ·· 0·93 (0·78–1·11) ·· ·· 1·01 (0·79–1·30) ··
Maternal 
education
14 0·62 12 0·02 8 0·22 7 0·24
None ·· 0·95 (0·83–1·09) ·· ·· 1·13 (0·97–1·31) ·· ·· 0·99 (0·86–1·13) ·· ·· 1·02 (0·88–1·18) ··
≥1 year 
formal 
education
·· 0·91 (0·84–1·00) ·· ·· 0·92 (0·83–1·01) ·· ·· 0·89 (0·81–0·98) ·· ·· 0·92 (0·82–1·02) ··
Skilled birth 
attendant
10 0·09 10 0·23 7 0·01 6 0·006
Yes ·· 0·87 (0·78–0·97) ·· ·· 1·00 (0·91–1·11) ·· ·· 1·00 (0·90–1·11) ·· ·· 1·06 (0·95–1·20) ··
No ·· 1·01 (0·88–1·15) ·· ·· 0·91 (0·80–1·03) ·· ·· 0·82 (0·74–0·92) ·· ·· 0·82 (0·71–0·95) ··
n=number of studies included in subgroup analysis.
Table 2: The effect of maternal multiple micronutrient supplements on stillbirth, neonatal mortality, mortality to 6 months, and infant mortality, stratified by potential effect 
modifiers
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birthweight, low birthweight, early preterm, preterm, and 
small-for-gestational-age births (Oken or Intergrowth 
standards; table 3 and appendix p 80, p 122). We also found 
multiple micronutrient supplements significantly 
increased the risk of being born large-for-gestational-age 
by the Intergrowth standard (RR 1·11, 95% CI 1·04–1·19; 
appendix p 150). There was no evidence that infant sex 
modified the effect of multiple micronutrient supplements 
Low birthweight (<2500 g) Preterm (<37 weeks) Small-for-gestational-age* Large-for-gestational-age*
n Relative risk (95% 
CI)
p value 
heterogeneity
n Relative risk  
(95% CI)
p value 
heterogeneity
n Relative risk 
(95% CI)
p value 
heterogeneity
n Relative risk  
(95% CI)
p value 
heterogeneity
Overall, fixed 
effects
17 0·88 (0·85–0·90) ·· 16 0·92 (0·88–0·95) ·· 16 0·97 (0·96–0·99) ·· 13 1·05 (0·95–1·15) ··
Overall, random 
effects
17 0·86 (0·81–0·92) ·· 16 0·93 (0·87–0·98) ·· 16 0·94 (0·90–0·98) ·· 13 1·04 (0·92–1·18) ··
Infant sex 17 ·· 0·48 15 ·· 0·63 15 ·· 0·62 12 ·· 0·18
Male ·· 0·87 (0·83–0·91) ·· ·· 0·93 (0·88–0·97) ·· ·· 0·97 (0·95–1·00) ·· ·· 1·11 (0·98–1·25) ··
Female ·· 0·89 (0·86–0·92) ·· ·· 0·91 (0·86–0·96) ·· ·· 0·98 (0·96–1·01) ·· ·· 0·98 (0·86–1·12) ··
Gestational age 
at enrolment
13 0·32 11 0·03 12 0·004 8 0·09
<20 weeks ·· 0·88 (0·86–0·91) ·· ·· 0·89 (0·85–0·93) ·· ·· 0·99 (0·97–1·01) ·· ·· 0·99 (0·86–1·13) ··
≥20 weeks ·· 0·84 (0·77–0·92) ·· ·· 1·00 (0·94–1·08) ·· ·· 0·91 (0·86–0·96) ·· ·· 1·18 (1·02–1·37) ··
Maternal 
adherence to 
regimen
12 0·61 10 0·62 11 0·43 8 0·88
<95% 
Adherence
·· 0·89 (0·85–0·92) ·· ·· 0·93 (0·88–0·97) ·· ·· 0·98 (0·96–1·01) ·· ·· 1·03 (0·90–1·18) ··
≥95% 
Adherence
·· 0·87 (0·84–0·91) ·· ·· 0·90 (0·85–0·96) ·· ·· 0·97 (0·94–1·00) ·· ·· 1·05 (0·90–1·22) ··
Maternal age 15 0·85 15 0·82 16 0·70 11 0·51
<20 years ·· 0·90 (0·86–0·93) ·· ·· 0·92 (0·87–0·98) ·· ·· 0·98 (0·95–1·00) ·· ·· 0·98 (0·79–1·22) ··
≥20 years ·· 0·90 (0·88–0·92) ·· ·· 0·92 (0·88–0·96) ·· ·· 0·97 (0·94–0·99) ·· ·· 1·06 (0·96–1·18) ··
Parity 16 0·88 14 0·63 15 0·94 10 0·09
First birth ·· 0·88 (0·85–0·92) ·· ·· 0·91 (0·86–0·96) ·· ·· 0·98 (0·95–1·00) ·· ·· 0·94 (0·78–1·12) ··
≥ Second 
birth
·· 0·88 (0·85–0·92) ·· ·· 0·92 (0·88–0·97) ·· ·· 0·97 (0·95–1·00) ·· ·· 1·12 (1·00–1·25) ··
Maternal BMI at 
enrolment
16 0·80 13 0·01 16 0·20 8 0·045
<18·5 kg/m2 ·· 0·88 (0·84–0·91) ·· ·· 0·84 (0·78–0·91) ·· ·· 1·00 (0·96–1·03) ·· ·· 0·77 (0·57–1·05) ··
≥18·5 kg/m2 ·· 0·88 (0·85–0·92) ·· ·· 0·94 (0·90–0·98) ·· ·· 0·97 (0·95–0·99) ·· ·· 1·08 (0·97–1·21) ··
Maternal height 16 0·16 15 0·58 16 0·27 10 0·17
<150 cm ·· 0·90 (0·87–0·93) ·· ·· 0·91 (0·86–0·96) ·· ·· 0·99 (0·96–1·01) ·· ·· 0·93 (0·78–1·12) ··
≥150 cm ·· 0·86 (0·82–0·90) ·· ·· 0·92 (0·88–0·97) ·· ·· 0·97 (0·96–0·99) ·· ·· 1·09 (0·97–1·22) ··
Maternal 
hemoglobin at 
enrolment
14 0·049 12 0·05 13 0·03 9 0·09
Anaemic 
(haemoglobin 
<110 g/L)
·· 0·81 (0·74–0·89) ·· ·· 0·98 (0·91–1·05) ·· ·· 0·92 (0·87–0·97) ·· ·· 1·25 (1·06–1·49) ··
Non-anaemic 
(haemoglobin 
≥110 g/L)
·· 0·91 (0·85–0·98) ·· ·· 0·88 (0·81–0·95) ·· ·· 0·99 (0·95–1·03) ·· ·· 0·99 (0·80–1·22) ··
Maternal 
education
16 0·75 14 0·64 15 0·049 9 0·75
None ·· 0·88 (0·84–0·93) ·· ·· 0·92 (0·87–0·98) ·· ·· 1·00 (0·97–1·03) ·· ·· 1·07 (0·88–1·29) ··
≥1 year 
formal 
education
·· 0·87 (0·84–0·91) ·· ·· 0·90 (0·87–0·95) ·· ·· 0·96 (0·94–0·98) ·· ·· 1·03 (0·92–1·16) ··
n=number of studies included in subgroup analysis. *As defined by the Oken standard.13
Table 3: The effect of maternal multiple micronutrient supplements on low birthweight, preterm birth, small-for-gestational-age birth, and large-for-gestational-age birth, stratified by 
potential effect modifiers
Articles
e1097 www.thelancet.com/lancetgh   Vol 5   November 2017
on low birthweight, prematurity, or small-for-gestational-
age births. Multiple micronutrient supplements had a 
greater effect on reducing the risk of low birthweight 
(RR 0·81; 95% CI 0·74–0·89) and small-for-gestational-age 
by Oken standard (0·92, 0·87–0·97) in anaemic pregnant 
women versus non-anaemic pregnant women (p values 
for heterogeneity 0·049 and 0·03, respectively; table 3). 
Maternal BMI modified the effect of multiple micronutrient 
supplements on several birth outcomes. Multiple 
micronutrient supplements reduced the risk of being born 
early preterm and preterm with greater magnitude among 
pregnant women with a BMI lower than 18·5 kg/m² 
compared with non-underweight pregnant women 
(table 3, appendix p 86). Maternal BMI also modified the 
risk of having a large-for-gestational-age birth based on the 
Oken standard (p value for heterogeneity 0·045); with non-
underweight women (BMI ≥18·5 kg/m²) having a greater 
increase in risk of large-for-gestational-age birth (table 4).
Gestational age at multiple micronutrient supplements 
initiation modified the effect of supplementation. Women 
initiating multiple micronutrient supplements before 
20 weeks gestation had greater reductions in the risk of 
preterm birth (RR 0·89, 95% CI 0·85–0·93; p value for 
heterogeneity 0·03; table 3). However, multiple 
micronutrient supplements provided greater reductions 
in the risk of small-for-gestational-age birth in women 
initiating supplementation after 20 weeks (RR 0·91, 
95% CI 0·86–0·96; p value heterogeneity 0·004; table 3). 
Multiple micronutrient supplements initiation before or 
after 20 weeks gestation conferred similar benefits in 
reducing the risk of low birthweight (table 3).
As a sensitivity analysis, we stratified studies by whether 
or not they used the same dose of iron in the multiple 
micronutrient supplements and iron-folic acid groups. 
The appendix provides overall estimates (appendix p 208) 
and subgroup estimates (appendix pp 209–217) of the 
effect of multiple micronutrient supplements for trials 
using the same dose of iron in the multiple micronutrient 
supplements and iron-folic acid alone groups versus trials 
using a lower dose iron in the multiple micronutrient 
supplements group than the iron-folic acid alone group 
(all used ≤30 mg iron for multiple micronutrient 
supplements and 60 mg iron for iron-folic acid alone). 
Among trials using the same dose of iron in both groups, 
the benefits of multiple micronutrient supplements were 
consistent with the primary analysis. By contrast, some 
subgroups given multiple micronutrient supplements 
with low dose iron (≤30 mg) had higher stillbirth and 
neonatal mortality than iron-folic acid alone with 60 mg 
iron. Specifically, multiple micronutrient supplements 
containing a lower dose of iron than the iron-folic acid 
comparison group were associated with an increased 
stillbirth rate among first pregnancies, early neonatal 
mortality in women who initiated supplementation 
before 20 weeks gestation, early neonatal and neonatal 
mortality in women with <95% adherence, and early 
neonatal mortality for multigravidae.
Discussion
Our findings show that pregnant women who take 
antenatal multiple micronutrient supplements including 
iron-folic acid have a lower risk of having a baby with low 
birthweight, a preterm birth, or having a small-for-
gestational-age baby. Furthermore, we identified several 
factors that modified the effect of multiple micronutrient 
supplements on infant survival and birth outcomes.
The effect of multiple micronutrient supplements on 
survival was modified by infant sex. Multiple micro-
nutrient supplements consistently reduced mortality by 
about 15% in females during the first year of life, but we 
did not record significant benefits in males. The 
biological mechanisms leading to these sex differences 
are not clear. West and colleagues31 and Lee and 
colleagues36 have previously proposed that sex differences 
in the mortality effect of multiple micronutrient 
supplements could be explained by differences in birth 
size by sex. Males have greater length, head 
circumference, and birthweight on average than females, 
and increased birth size due to multiple micronutrient 
supplements might lead to greater birth complications in 
males.37 However, we noted no sex differences in the 
effect of multiple micronutrient supplements on 
stillbirth, which suggests that effect modification by sex 
might operate through other mechanisms or vary with 
the population context. The burden of infections and 
leading causes of mortality have been shown to vary by 
infant sex;38,39 additional information about the causes 
and timing of deaths within trials might help clarify why 
multiple micronutrient supplements seem to be more 
beneficial for female infants. Nevertheless, we do not 
recommend programmes considering implementation 
of multiple micronutrient supplements target only 
pregnant women carrying female fetuses as both male 
and female neonates experience birthweight benefits and 
small positive survival benefits are possible in males.
Multiple micronutrient supplements had a bigger effect 
on birth outcomes in women with poor nutritional status, 
as indicated by anaemia or low BMI, at the start of 
supplementation, as initially reported in the SUMMIT 
study.26 Anaemic women had greater reductions in the 
risk of low birthweight, small-for-gestational-age birth, 
and mortality to 6 months than non-anaemic pregnant 
women. The effect of multiple micronutrient supplements 
on preterm birth was also greater for pregnant women 
who had a BMI of lower than 18·5 kg/m² at the start of 
supplementation. These findings suggest that iron-folic 
acid alone is likely an insufficient intervention for 
anaemic pregnant women and justifies continued focus 
on anaemia and low BMI as key effect modifiers for 
nutrition interventions in pregnancy. A recent multiple 
micronutrient supplements trial34 done in China among 
non-anaemic and mildly anaemic women (not included 
in our meta-analysis) found no effect of multiple 
micronutrient supplements on perinatal mortality and a 
non-significant 10% reduction in low birthweight. These 
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findings are consistent with our non-anaemic subgroup 
results, which showed no effect of multiple micronutrient 
supplements on early neonatal, neonatal, or infant 
mortality and an 8% reduction in low birthweight.
Due to the clustering of protein-energy and 
micronutrient deficiencies, we cannot directly examine 
whether improvement in maternal haemoglobin status 
mediated a greater effect of multiple micronutrient 
supplements on low birthweight in anaemic women. 
Anaemia might be a proxy for deficiencies of 
micronutrients included in multiple micronutrient 
supplements, as well as numerous other factors including 
maternal infection.40,41 Findings of a previous meta-
analysis showed that multiple micronutrient supplements 
(which included iron) had a similar effect on haemoglobin 
and anaemia than iron alone or iron with folic acid.42 
Notably, some trials included in our meta-analysis and the 
anaemia meta-analysis used higher dose iron in the 
control group than the multiple micronutrient supple-
ments arm, which might have attenuated the 
haemoglobin, mortality, and birth outcome effects of 
multiple micronutrient supplements, particularly in 
anaemic pregnant women.20,21,27–29,32,33,35,42 Despite this, we 
still find a larger effect of multiple micronutrient 
supplements among anaemic than for non-anaemic 
pregnant women. There are several haemoglobin 
independent pathways by which multiple micronutrient 
supplements might improve birth outcomes,5 including 
reductions in maternal and fetal inflammation,43 
improvements in oxidative metabolism and placental 
function,44,45 and altered maternal endocrine effects.46 
Although the biological mechanisms through which 
multiple micronutrient supplements provides benefits are 
unclear, our meta-analysis indicates that the population-
level benefits for birth outcomes are likely to be greater in 
settings with high rates of maternal nutritional 
deficiencies. It is also important to note that in the 
MINIMat trial women who received both early food 
supplementation and multiple micronutrient supple-
ments had the lowest rate of infant mortality;30 combined 
macronutrient and micronutrient interventions might 
produce even greater effects in settings with high rates of 
maternal malnutrition.
We did not identify any subgroup that experienced 
significantly elevated risk of stillbirth or mortality at any 
timepoint in the primary analysis. Multiple micronutrient 
supplements trial reports have raised concerns that 
increased birth size due to multiple micronutrient 
supplements may increase the risk of cephalopelvic 
disproportion and neonatal asphyxia, particularly among 
women of small stature.17,31 We found that multiple 
micronutrient supplements indeed increased the risk of 
large-for-gestational-age births (as defined by the 
Intergrowth standard14), which could hypothetically 
increase the risk of maternal-fetal disproportion and 
related birth complications. However, we found no 
indication that mothers who took multiple micronutrient 
supplements and whose height was less than 150 cm had 
increased risk of stillbirth or mortality at any timepoint. 
As such, alternative interpretations or mechanisms to 
explain no overall effect of multiple micronutrient 
supplements on mortality should be explored.
We also provide evidence that iron dosage influences 
the observed effect of multiple micronutrient 
supplements on stillbirth and mortality. Specifically, the 
sensitivity analyses revealed benefits and no significant 
harmful effects overall or in any subgroup among trials 
that used the same dose of iron in the multiple 
micronutrient supplements and iron-folic acid alone 
arms. By contrast, the sensitivity analyses also found that 
multiple micronutrient supplements with low dose iron 
(<30 mg) results in a higher observed stillbirth and 
mortality in some subgroups when compared to iron-
folic acid alone with 60 mg iron. The most recent 
Cochrane Review found similar effect modification by 
iron dose on perinatal mortality.6 Furthermore, the WHO 
antenatal care guidelines noted the potential for harmful 
effects of multiple micronutrient supplements on 
neonatal mortality among a subgroup analysis in which 
5 out of 6 trials used low dose iron (≤30 mg) in the 
multiple micronutrient supplements group and 60 mg 
iron in the iron-folic acid alone group.10 Taken together 
with previous analyses, our data suggest that both iron 
and multiple micronutrients have beneficial effects and 
that multiple micronutrients together with iron-folic acid 
provide even greater benefits than iron-folic acid alone. 
Accordingly, countries and programmes considering 
implementation of multiple micronutrient supplements 
should use a formulation with an iron dose similar to 
what they currently use; for example, multiple 
micronutrient supplements that contains 60 mg iron 
should be considered in settings where 60 mg iron-folic 
acid is currently implemented.
Notwithstanding the large sample size and consistency 
of our findings, there are several limitations to our meta-
analysis. First, because of the number of subgroup 
analyses we did, there is an increased risk of type 1 errors 
inherent to the number of heterogeneity tests presented. 
However, our findings as a whole exceed those that 
would be expected by chance; 13 of 70 tests for 
heterogeneity for mortality outcomes were significant 
(probability of occurring by chance alone <0·01%). 
There is also low probability of finding 26 of 
146 subgroups had significant survival benefits (<0·01%) 
and that no subgroups had increased mortality risk 
(2·5%) if we construct a hypothesis assuming there was 
no true effect of multiple micronutrient supplements on 
mortality in any subgroup. Second, as previously 
discussed, some trials used a higher dose of iron in the 
control group as compared with the multiple 
micronutrient supplements group, and our sensitivity 
analysis suggests that inclusion of these trials resulted 
in attenuation of the effect of multiple micronutrient 
supplementation because the iron-folic acid alone group 
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participants might have experienced benefits from 
additional iron.20,21,27–29,32,33 Third, the JiVitA-331 and 
SUMMIT26 trials are weighted heavily in many of the 
subgroup strata because of their large sample sizes and 
high event rates. Our sensitivity analyses show that sex 
differences in the effect of multiple micronutrient 
supplements on neonatal mortality are robust to 
excluding either of these studies (appendix pp 218–220). 
However, the stronger benefit of multiple micronutrient 
supplements on 6-month mortality in infants born to 
anaemic women is driven by the SUMMIT study,26 and 
the stronger benefit of multiple micronutrient 
supplements on preterm birth among infants born to 
underweight women and infant mortality among male 
infants, are driven by JiVitA-331 (appendix  pp 218–220). 
Fourth, we were unable to examine HIV as a potential 
effect modifier since only two trials included both HIV-
infected and HIV-uninfected women. Nevertheless, 
there was no indication that the effect of multiple 
micronutrient supplements varied by maternal HIV 
status in these studies.19,32 Finally, although our analysis 
identified several maternal and child factors that alter 
the effect of multiple micronutrient supplements on 
mortality and birth outcomes, we can provide only 
limited insight into the biological mechanisms through 
which multiple micronutrient supplements may operate. 
As poor socioeconomic status, significant barriers to 
health services, and nutritional deficiencies often 
coexist, the effect modifiers we examined in this analysis 
(eg, skilled birth attendants, maternal underweight, and 
maternal anaemia) have overlap as indicators of 
underlying adversity. Even so, the factors identified in 
this paper suggest subgroups that might experience the 
greatest benefits from multiple micronutrient 
supplements, irrespective of the mechanisms through 
which multiple micronutrient supplements operates.
Our findings established that multiple micronutrient 
supplements reduced mortality in female neonates, and 
although multiple micronutrient supplements increased 
birthweight and reduced preterm among all infants, the 
greatest effects were for those born to pregnant women 
with nutritional deficiency as indicated by anaemia or low 
BMI. Based on the included data and methods of this 
study, we also found none of the 26 subgroups, or the 
population overall, showed multiple micronutrient 
supplements significantly increased the risk of stillbirth or 
neonatal, six-month, or infant mortality. A systematic 
review47 that assessed the long-term health effects noted no 
significant evidence that multiple micronutrient 
supplements improved child growth, body composition, 
blood pressure, respiratory, or cognitive outcomes as 
compared with iron folic-acid alone. However, a recently 
published long-term follow-up study48 of SUMMIT found 
that multiple micronutrient supplements significantly 
improved procedural memory and produced better scores 
on 18 of 21 cognitive tests among Indonesian children 
aged 9–12 years. 
This new evidence suggests that WHO should consider 
re-evaluating the balance of benefits and harms of 
universal multiple micronutrient supplements in their 
antenatal care recommendations. Programmes and low-
income and middle-income countries considering 
implementation of multiple micronutrient supplements 
have the opportunity to simultaneously expand coverage of 
early antenatal care attendance and multiple micronutrient 
supplements including iron-folic acid, while also 
improving the quality of antenatal care counselling and 
services to produce population-level infant health benefits, 
which might be greater than any of these strategies in 
isolation. Packaging multiple micronutrient supplements 
with effective antenatal care interventions for coordinated 
delivery is consistent with the Sustainable Development 
Goals, which emphasise the identification of intervention 
synergies that have the potential for rapid impact.49
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